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menstrual cycle. Measurements were done at onset of menstrua-
tion (day 0), and at days 7, 14, and 21.
Hemoglobin levels changed during the cycle, the lowest one
was observed on day 21 and was more marked in women with-
out hormonal contraception. Our data do not support a speciﬁc
role of progesterone, since it was low in the ﬁrst 14 days and in
the hormonal contraception group throughout the menstrual
cycle (Fig. 1). Since patients on antiviral therapy are required to
use contraception, it is likely that the difference in anemia in pre-
menopausal women in our study is in part due to hormonal con-
traception. Unfortunately, as mentioned in the paper, we did not
record the type of contraception. We cannot exclude the effect of
synthetic gestagens on hemolysis caused by ribavirin. Further
studies are ongoing to better understand why young females
have less anemia than menopausal women and men of all ages.
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Fig. 1. Progesterone levels in healthy women with or without hormonal
contraception during one menstrual cycle. All hormonal contraceptives con-
tained ethinyl estradiol combined with a synthetic progestagen (3 dydrogester-
one, 2 drospirenone, 1 of each: desogestrel, levonorgestrel, cyproterone,
chlormadinone, gestodene).
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,To the Editor:
We note, with interest, the ﬁndings of the interim results from
the CUPIC study reported recently in the Journal of Hepatology
[1]. The authors demonstrate a high incidence of serious adverse
events (40.0%), and of death and severe complications (severe
infection or hepatic decompensation) (6.4%), in a difﬁcult to treat
cohort of patients. Most notably however, the authors have
proposed that compensated cirrhotic patients with chronic HCV
with both thrombycytopaenia (platelets <100,000) and hypoalbu-
minaemia (<35 g/dl) should not be treated with triple therapy.
There are a number of important considerations for accurate
interpretation of the data. Although acknowledged by the
authors, it is important to re-emphasise that CUPIC lacked a con-
trol group. The author’s conclusions must, therefore, be balanced
against the published natural history of HCV cirrhotic patients
The beneﬁts of sustained virologic response (SVR) in this group
are well documented [2]. Hence, international treatment guide-
lines generally recommend antiviral therapy in this patient group
[3,4]. Indeed, in controlled trials of dual therapy of patients with
decompensated cirrhosis, the treatment group had more favour-
able outcomes compared to the control group [5]. Additionally
treatment of HCV patients on the liver transplant waiting list
does not appear to increase overall mortality compared withJournal of Hepatology 201
er CC BY-NC-ND license.untreated patients [6]. Thus, the beneﬁts of achieving SVR, in this
difﬁcult population, cannot be overstated [7].
CUPIC was not designed or powered for interim safety analy-
sis. Indeed recent data investigating the therapeutic potential of
triple therapy in patients with severe ﬁbrosis or cirrhosis demon-
strated lower complication rates than those observed in CUPIC
[8,9]. Possible explanations for this difference include multiple
treatment centres (n = 56) with variation in the treatment and
monitoring protocols. In addition ‘severe infection’ is not clearly
deﬁned in the manuscript and this was the most commonly (24
of 32 cases) reported severe complication. Indeed, 7 of the 24
patients who survived a severe infection continued on treatment
without requiring a dose reduction and a further unreported
number continued treatment at a reduced dose. Deaths in the
total cohort were relatively uncommon (n = 6, <1%); however,
neither the albumin level nor platelet count is reported for these.
Two of the six deaths reported occurred prior to the introduction
of the protease inhibitor which, may indicate that these subjects
were poor candidates for treatment.
The association between platelet count and albumin level and
mortality during HCV treatment is not novel. Previous work has
demonstrated a per annum mortality for HCV patients with
thrombocytopaenia alone (deﬁned as platelet count <150,0004 vol. 60 j 894–901 899
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rather than the level of 100,000 used in the paper) of 4%, which
would correspond to 4 deaths over the course of a year
among the 103 thrombocytopaenic patients [10]. Furthermore,
hypoalbuminaemia has also been independently associated with
increased mortality in cirrhotic patients prompting calls for the
adoption of a modiﬁed MELD score incorporating albumin [11].
It seems incontrovertible that cirrhotic patients are at greater risk
of complication from triple therapy, but suggesting that platelet
count (<100,000) and albumin level (<35) should preclude con-
sideration for treatment without describing the natural history
of untreated HCV in a similar cohort appears unbalanced. For
many of these patients, the promise shown in clinical trials of
the next generation of directly acting antivirals, the safety of
which in these cohorts remains also untested may well come
too late.
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To the Editor:
Schmidt-Martin and colleagues raised one comment regarding
the main recommendation of our article meaning that patients
with hypoalbuminemia (<35 g/dl) and thrombocytopaenia
(6100,000/mm3) should not be treated with an interferon based
triple therapy due to the high risk to develop severe complications
during the ﬁrst 16 weeks of therapy [1]. As mentioned in the sup-
plementary materials, severe complications were deﬁned as any
of death, grade 3 or 4 infection, hepatic decompensation. The
cause of death, the description of severe infections and hepatic
decompensation were detailed in the results section. A severe
infection (grade 3 or 4) was deﬁned by an infectious episode need-
ing hospitalisation or life-threatening. Among the 6 patients who
died during the ﬁrst weeks of treatment, 3 had hypoalbuminemia
(<35 g/dl) and thrombocytopenia (6100,000/mm3) and the 3
others either hypoalbuminemia or thrombocytopenia.
CUPIC was a cohort in setting of the French early access pro-
gram explaining that all patients received antiviral therapy and
the lack of control group. In ﬁve recent studies (including a
meta-analysis) evaluating the natural history of cirrhotic patients
900 Journal of Hepatology 2guideline by the American Association for the Study of Liver Diseases.
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with characteristics comparable to those from the CUPIC cohort,
the annual incidence of deaths and/or liver decompensation var-
ied from 6.2 to 11% on treatment, challenging the indication for
triple therapy in this subgroup of patients [2–6]. In the subgroup
of patients who combined both predictors of severe complica-
tions (albumin <35 g/dl and platelet count 6100,000/mm3), their
occurrence was 44.1% during the ﬁrst 16 weeks. We cannot
exclude that this rate could increase overtime in patients receiv-
ing 48 weeks of therapy. This result strongly suggests that the
risk to develop severe complications is higher in patients with
both predictors treated with triple therapy compared to
untreated cirrhotic patients. We agree that the lack of a control
group does not allow us to distinguish between severe events
caused by treatment from those caused by the cirrhosis itself.
However, based on comparisons with other studies in cirrhotic
patients, the rate of observed severe events was much higher in
this particular group of patient with advanced cirrhosis, low
platelet count and low albumin level. Moreover severe infection
is a relatively rare event in non-treated compensated viral cirrho-
sis. Therefore, it’s likely that the treatment contributed to these
014 vol. 60 j 894–901
